US stocks surged | Tourmaline Bio (TRML.US) was acquired by Novartis for about $1.4 billion, with a increase of over 57%

According to the Wise Financial APP, on Tuesday, Tourmaline Bio (TRML.US) surged over 57%, reaching a three-year high of $47.62. In terms of news, Novartis has agreed to acquire the company in an all-cash deal worth approximately $1.4 billion. Shareholders of Tourmaline will receive $48 per share in this transaction, and the company will become an indirect wholly-owned subsidiary of Novartis. The transaction is expected to be completed in the fourth quarter of 2025.